Literature DB >> 16175118

Longitudinal incision in surgical release of De Quervain disease.

Hakan Gundes1, Bilgehan Tosun.   

Abstract

The objective of this paper is to contrast the use of a longitudinal incision in surgical decompression of De Quervain disease with a transverse incision. The advantages are ease in recognition of compartment variations and superficial branches of radial nerve and prevention of palmar tendon subluxation by permitting a more dorsal release of the compartment sheath. Since 2002, we have used a longitudinal skin incision instead of the classic transverse incision to release the first dorsal compartment.

Mesh:

Year:  2005        PMID: 16175118     DOI: 10.1097/01.bth.0000181105.24124.c0

Source DB:  PubMed          Journal:  Tech Hand Up Extrem Surg        ISSN: 1089-3393


  5 in total

1.  De qeurvian tenosynovitis: clinical outcomes of surgical treatment with longitudinal and transverse incision.

Authors:  Syyed Jalil Abrisham; Mohammad Hosein Akhavan Karbasi; Jalil Zare; Zahra Behnamfar; Arefah Dehghani Tafti; Behzad Shishesaz
Journal:  Oman Med J       Date:  2011-03

Review 2.  Effectiveness of surgical interventions for treating de Quervain's disease: A systematic review and meta-analysis.

Authors:  Sitthiphong Suwannaphisit; Chaiwat Chuaychoosakoon
Journal:  Ann Med Surg (Lond)       Date:  2022-04-13

3.  Functional outcome of De Quervain's tenosynovitis with longitudinal incision in surgically treated patients.

Authors:  H J Mangukiya; A Kale; N P Mahajan; U Ramteke; J Manna
Journal:  Musculoskelet Surg       Date:  2019-01-01

4.  Optimal surgical approach for the treatment of Quervains disease: A surgical-anatomical study.

Authors:  Alexander R Poublon; Gert-Jan Kleinrensink; Anton LA Kerver; J Henk Coert; Erik T Walbeehm
Journal:  World J Orthop       Date:  2018-02-18

5.  A novel classification of the anatomical variations of the first extensor compartment.

Authors:  Zheng-Yu Gao; Hao Tao; Hao Xu; Jun-Qiang Xue; Yao Ou-Yang; Ji-Xia Wu
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.